Listen in: Bardy Diagnostics raises $35.5M for heart rate monitor technology

by Quinten Dol
April 16, 2019
bardy diagnostics raises $35.5 million
photo via bardy diagnostics

The human body is a somewhat turbulent place, with organs pumping and fluids sloshing around — and all that motion and noise makes it hard for heart doctors to obtain detailed electrocardiography readings, used to detect arrhythmia.

However, by focusing on P-waves — one of two main types of seismic waves in the body — Seattle-based Bardy Diagnostics says it can detect the rhythm of a heartbeat with more precision than other monitors. That claim received a big boost yesterday, with the company’s announcement of a $35.5 million Series B funding round, led by Ohio and North Carolina-based River Cities Capital Funds.

 

Our Series B capital will continue to fuel the technological innovation that Dr. Bardy has always insisted on and for which BardyDx has come to be known.”

 

The company plans to use the funds to hire more members to its sales team and expand its monitoring services and double down on technological investments on the back end.

“For nearly 60 years, standard ECG engineering practices have over-processed the heart’s electrical message to make machines’ ‘lives’ easier at the expense of losing details in the ECG,” CEO Dr. Gust Bardy said in a statement. “In essence, such legacy engineering doesn’t listen to what the heart is trying to tell us but rather tells the heart what we are willing to hear.”

“At BardyDx, our pioneering technology focuses on revealing the cardiac rhythm message fully, and in so doing, allows for precise and meaningful patient management predicated on cardiac truth.”

Dr. Bardy is a cardiac electrophysiologist who serves as the University of Washington’s Clinical Professor of Medicine, Cardiology, and directs the Seattle Institute for Cardiac Research.

 

dr gust bardy seattle tech startup
photo via bardy diagnostics

The company’s heart rate monitor is designed to be worn in the center of the chest to collect the low amplitude, low frequency signals that constitute the P-wave. Physicians access and analyze through the company’s web portal.

“Our Series B capital will continue to fuel the technological innovation that Dr. Bardy has always insisted on and for which BardyDx has come to be known,” Chief Operating Officer Mark Handfelt said in the statement.

In addition to River Cities, HealthQuest Capital, Aperture Venture Partners, Aphelion Capital, Lumira Ventures and Rex Health Ventures all joined the round as new investors.  

Jobs at Bardy Diagnostics

Seattle startup guides

LOCAL GUIDE
Best Companies to Work for in Seattle
LOCAL GUIDE
Coolest Tech Offices in Seattle
LOCAL GUIDE
Best Benefits at Seattle Tech Companies
LOCAL GUIDE
Women in Seattle Tech